Current Role of Anthracyclines in the Treatment of Multiple Myeloma

  • Sikander Ailawadhi
  • Asher Chanan-Khan
Part of the Contemporary Hematology book series (CH)


Anthracyclines are an important class of antineoplastic drugs that have undergone extensive preclinical and clinical evaluation in various neoplastic disorders including multiple myeloma (MM). They remain an important ingredient in various therapeutic regimens for several hematologic cancers with major impact as part of combination chemotherapy regimens. In MM, anthracy-clines (doxorubicin) remain an integral part of the frontline VA D (vincristine, doxorubicin, and dexamethasone) regimen, which is one of the most common antimyeloma regimens used worldwide. This chapter will thus focus on the current role of anthracyclines in the management of patients with MM.


Anthracyclines are naturally occurring antibiotics that are derived from actinobacteria Streptomyces peucetius var. caesius. Daunorubicin was the first agent to be discovered in this category that demonstrated antitumor activity in murine model system of human cancers. Further development of this class...


Overall Survival Multiple Myeloma Maximum Tolerate Dose Overall Response Rate Pegylated Liposomal Doxorubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Chu E, DeVita VC. Physician's cancer chemotherapy drug manual. Sudbury, MA: Jones and Bartlett; 2006.Google Scholar
  2. 2.
    Robert J. Anthracyclines. In: A clinician's guide to chemotherapy pharmacokinet-ics and pharmacodynamics. Vol. 93 (3rd edition). Baltimore, MD: Williams 8 Wilkins; 1983.Google Scholar
  3. 3.
    Sharpe M, Easthope SE, Keating GM, et al. Polyethylene-glycol-liposomal doxoru-bicin: A review of its use in the management of solid and hematological malignancies and AIDS-related kaposi's sarcoma. Drugs. 2002;62:2089–2126.PubMedCrossRefGoogle Scholar
  4. 4.
    Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19:424–436.PubMedCrossRefGoogle Scholar
  5. 5.
    Hussein MA, Wood L, Hsi E, et al. A phase II trial of pegylated liposomal doxo-rubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 2002;95:2160–2168.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee CC, Gillies ER, Fox ME, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. PNAS. 2006;103:16649–16654.PubMedCrossRefGoogle Scholar
  7. 7.
    Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466.PubMedCrossRefGoogle Scholar
  8. 8.
    Doroshow JH. Anthracyclines and anthracenediones. In: Cancer chemotherapy and biotherapy: Principles and practice. Vol. 500 (3rd edition). Philadelphia, PA: Lippincott Williams 8 Wilkins; 2001.Google Scholar
  9. 9.
    Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340.PubMedCrossRefGoogle Scholar
  10. 10.
    Alexanian R, Barlogie B, Tucker S VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33:86–89.PubMedCrossRefGoogle Scholar
  11. 11.
    Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;2: 882–885.PubMedCrossRefGoogle Scholar
  12. 12.
    Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma. Cancer. 2006;106:848–858.PubMedCrossRefGoogle Scholar
  13. 13.
    Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. Ann Oncol. 2004;15:134–138.PubMedCrossRefGoogle Scholar
  14. 14.
    Offidani M, Corvatta L, Piersantelli M, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108:2159–2164.PubMedCrossRefGoogle Scholar
  15. 15.
    Deauna-Limayo D Aljitawi O, Mayo M, et al. Pegylated liposomal doxorubicin (Doxil®), dexamethasone and low dose thalidomide (DDt) as therapy for newly diagnosed multiple myeloma. Blood. 2005;106:Abstract 5164.Google Scholar
  16. 16.
    Orlowski RZ, Baldwin AS Jr. NF-kappa B as a therapeutic target in cancer. Trends Mol Med. 2002;8:385–389.PubMedCrossRefGoogle Scholar
  17. 17.
    Ma MH, Yang HH, Parker K, et al. The proteasome prohibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–1144.Google Scholar
  18. 18.
    Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood. 2003;101:2377–2380.PubMedCrossRefGoogle Scholar
  19. 19.
    Orlowski RZ, Peterson BL, Sanford B, et al. Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for adult patients with symptomatic multiple myeloma: Cancer and leukemia group B study 10301. Blood. 2006;108:Abstract 797.Google Scholar
  20. 20.
    Jakubowiak AJ, Brackett L, Kendall T, et al. Combination therapy with Velcade, Doxil, and Dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM). Blood. 2005;106:Abstract 5179.Google Scholar
  21. 21.
    Jakubowiak A, Al-Zoubi A, Kendall T, et al. Combination therapy with bortezomib(Velcade®), Doxilê, and dexamethasone(VDD) in newly diagnosed myeloma: updated results of phase II clinical trial. Haematologica. 2007;92:Abstract PO-721.Google Scholar
  22. 22.
    Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–1356.PubMedCrossRefGoogle Scholar
  23. 23.
    Palva IP, Ahrenberg P, Ala Harja K, et al. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish leukaemia group. Eur J Haematol. 1990;44:121–124.PubMedCrossRefGoogle Scholar
  24. 24.
    Hussein MA, Elson P, Tsoe EA, et al. Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). Blood [abstract]. 2002;100:403a.CrossRefGoogle Scholar
  25. 25.
    Baz R, Choueiri TK, Abou Jawde R, et al. Doxil (D), Vincristine (V), reduced frequency Dexamethasone (d) and Revlimid(R) (DVd-R) results in a high response rate in patients with refractory multiple myeloma (RMM). Blood. 2005;106: Abstract 2559.Google Scholar
  26. 26.
    Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematological malignancies. Blood. 2005;105:3058–3065.PubMedCrossRefGoogle Scholar
  27. 27.
    Orlowski RZ, Zhuang SH, Parekh T, et al. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. Blood. 2006;108: Abstract 404.Google Scholar
  28. 28.
    Chanan-Khan AA, Padmanabhan S, Miller KC, et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rate in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma. Blood. 2006;108:Abstract 3539.Google Scholar
  29. 29.
    San-Miguel JF, Hajek R, Nagler A, et al. Doxil®+Velcadeê in previously treated ≥ 65y myeloma pts. Haematologica. 2007;92:PO-620.Google Scholar
  30. 30.
    Ciolli S, Leoni F, Casini C, et al. Liposomal doxorubicin (Myocetê) enhance the efficacy of bortezomib, dexamethasone plus thalidomide in refractory myeloma. Blood. 2006;108:Abstract 5087.Google Scholar
  31. 31.
    Chari A, Kaplan L, Linker C, et al. Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma. Blood. 2005;106:Abstract 5182.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sikander Ailawadhi
    • 1
  • Asher Chanan-Khan
    • 1
  1. 1.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations